Search
Close this search box.

A Novel Beads-free CAR T-Cell Manufacturing Platform

Chimeric antigen receptors (CARs) T-cell therapy has become an important approach for cancer treatment. This project aims develop a novel perfusion-based, beads-free, bioreactor system as a new platform for CAR T cell manufacturing with the intent to simp
Categories
Cell and Gene therapies
Project status
100% Completed

Solution

Performance Period: 4/1/2021 to 5/31/2023

Chimeric antigen receptors (CARs) T-cell therapy has become an important approach for cancer treatment. This project aims develop a novel perfusion-based, beads-free, bioreactor system as a new platform for CAR T cell manufacturing with the intent to simplify the manufacturing process and form the foundation for achieving full automation. The system is designed to facilitate scaling the manufacturing of CAR T cells for different uses, which can then be applied across a broad array of T-cell based applications. The approach aims to reduce development costs, shorten timelines, and bring direct benefit to patients. 

Outcomes and Impacts

The development of this novel perfusion-based system would facilitate scaling the manufacturing of CAR T cells for different users.

Updates, Related Publications, and Deliverables

  • Login to the NIIMBL member portal for access to project updates, related publications, and deliverables. 

Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Project Lead

Southwest Research Institute

Southwest Research Institute

Participating Organizations

Genentech

Genentech

Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC

University of Pennsylvania

University of Pennsylvania

Xcellerate Biotech Inc.

Xcellerate Biotech Inc.